Tarsus Pharmaceuticals Inc (TARS) — Cash Flow-to-Debt Ratio
Tarsus Pharmaceuticals Inc (TARS) has a Cash Flow-to-Debt Ratio of 0.25x as of June 2026, meaning its operating cash flow of $66.77 Million could theoretically repay 0% of its total liabilities ($264.41 Million) in one year. See Tarsus Pharmaceuticals Inc free cash flow to debt ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Tarsus Pharmaceuticals Inc Cash Flow-to-Debt Ratio (2018–2025)
Historical debt coverage capacity for Tarsus Pharmaceuticals Inc across 8 annual periods. For the full cash flow conversion analysis, see Tarsus Pharmaceuticals Inc (TARS) cash conversion ratio.
Annual Cash Flow-to-Debt Ratio for Tarsus Pharmaceuticals Inc (2018–2025)
Year-by-year debt coverage analysis for Tarsus Pharmaceuticals Inc. Check TARS cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.06x | $-12.45 Million | $218.73 Million | ▲ +89.5% |
| 2024 | -0.54x | $-83.03 Million | $152.46 Million | ▲ +68.2% |
| 2023 | -1.72x | $-117.49 Million | $68.50 Million | ▼ -22.3% |
| 2022 | -1.40x | $-49.03 Million | $34.96 Million | ▼ -555.6% |
| 2021 | 0.31x | $3.75 Million | $12.18 Million | ▲ +108.7% |
| 2020 | -3.53x | $-21.14 Million | $5.99 Million | ▼ -6077.7% |
| 2019 | -0.06x | $-3.67 Million | $64.32 Million | ▲ +81.9% |
| 2018 | -0.32x | $-1.18 Million | $3.74 Million | — |